Lilly's retatrutide doubles weight loss of Ozempic in head-to-head trial
Lilly's retatrutide caused 20 per cent weight loss, double Ozempic's 9 per cent, and improved blood-sugar control more.
Eli Lilly announced that retatrutide, an experimental once-weekly injection, outperformed Ozempic in a Phase 3 trial. The trial represents one of several Phase 3 trials of the drug.
Participants taking retatrutide lost 20 to 21 per cent of their body weight over 80 weeks. The weight loss more than doubles the 9 per cent loss on Ozempic's highest approved dose.
Blood sugar control improved more with retatrutide. It lowered A1C by 2.2 per cent versus 1.8 per cent with Ozempic.
Retatrutide also showed greater improvements in cholesterol, triglycerides and blood pressure. The most common side effects were gastrointestinal: diarrhea, nausea and constipation.
About 8 per cent of retatrutide users stopped the drug because of side effects. Only 3 per cent stopped Ozempic.
Retatrutide has not yet been approved by regulators anywhere.
- 44.3-47.4 lbs (19.5-20.9%)
- Retatrutide weight loss
- 20.9 lbs (9.4%)
- Ozempic weight loss
- 2.2%
- Retatrutide A1C reduction
- 80 weeks
- Trial duration
Why it mattersIf approved, retatrutide could become a stronger option for people struggling to lose weight. Current diabetes medications don't work as well for them.
AustraliaAustralian patients with type 2 diabetes may access a more effective treatment if retatrutide gains regulatory approval, likely within the next year or two.
✓ Claims checked against the source. checked 4 h ago
